Use of sibutramine in obese Hispanic adolescents.
A study on the treatment of obese adolescents with the use of sibutramine in private practice is presented. Patients consisted of 24 boys and 43 girls with obesity (body mass index [BMI]>85th percentile sex-specific BMI for age and sex) ranging from 12 to 18 years of age. Patients were given sibutramine 10 mg per day for 6 months. With the last observation carried forward adjustment, after 6 months of treatment, patients' average weight changed from 91.6+/-19.7 kg to 81.9+/-19.0 kg (P<.001), that is, 89.5+/-7.3% of initial weight. The most frequently reported adverse events included increased blood pressure and pulse rate (n=7), constipation (n=8), dry mouth (n=4), and constipation and dry mouth (n=3). Sibutramine may be considered effective for the treatment of obese adolescents, with a level of safety similar to that observed in adult patients.
Violante-Ortìz
Rafael
R
Regional General Hospital, Tamaulipas, Mexico.
Del-Rio-Navarro
Blanca Estela
BE
Lara-Esqueda
Agustìn
A
Pèrez
Pedro
P
Fanghänel
Guillermo
G
Madero
Agustìn
A
Berber
Arturo
A
D000293:Adolescent; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002648:Child; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008800:Mexico; D009765:Obesity / Q000188:drug therapy*
D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine